Evidence Snapshot

Tyrosine-protein kinase FRK

CHEMBL4223 SINGLE PROTEIN Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:31:09Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 7:31 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL4223

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Tyrosine-protein kinase FRK as ChEMBL target CHEMBL4223, mapped to UniProt P42685. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Tyrosine-protein kinase FRK

SINGLE PROTEIN · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL4223

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

P42685

Tyrosine-protein kinase FRK

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Tyrosine-protein kinase FRK matters

As of 2026-09-13

Tyrosine-protein kinase FRK is reviewed as Tyrosine-protein kinase FRK (UniProt P42685); Tyrosine-protein kinase FRK shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 35 approved drugs, 1628 compounds, and 261 assays, with lead potency reaching pChEMBL 9.5.

Protein context

Tyrosine-protein kinase FRK

Tyrosine-protein kinase FRK Sequence length is 505 aa.

Review this target as Tyrosine-protein kinase FRK, mapped to UniProt P42685. Sequence length is 505 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt P42685 Protein

Disease context

cancer

Tyrosine-protein kinase FRK shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include REGORAFENIB.

Start review with cancer because it currently carries approved-linked support. Linked drugs include REGORAFENIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Approved-linked 1 linked drug

Activity base

Portfolio and assay base

ChEMBL currently tracks 35 approved drugs, 1628 compounds, and 261 assays for this target. The dominant activity type is KI. CHEMBL5416410 is the current potency anchor at pChEMBL 9.5.

Use CHEMBL5416410 as the tractability anchor when discussing potency (pChEMBL 9.5).

Activity source · ChEMBL 36 via Core Engine

35 approved pChEMBL 9.5

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Tyrosine-protein kinase FRK matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P42685, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why cancer is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1628

Total Compounds

261

Total Assays

Approved Drugs

IC50: 82.0, KI: 497.0, KD: 401.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL5416410	9.5	Kd	Approved
No preferred name CHEMBL1984162	9.0	Ki	—
No preferred name CHEMBL1993661	9.0	Ki	—
No preferred name CHEMBL400402	9.0	Kd	—
No preferred name CHEMBL1981047	8.9	Ki	—

Approved Drugs

Structure	Compound	First Approval
	TOVORAFENIB CHEMBL3348923	2024
	ZANUBRUTINIB CHEMBL3936761	2019
	ENTRECTINIB CHEMBL1983268	2019
	FEDRATINIB CHEMBL1287853	2019
	LORLATINIB CHEMBL3286830	2018
	BRIGATINIB CHEMBL3545311	2017
	TIVOZANIB CHEMBL1289494	2017
	DABRAFENIB CHEMBL2028663	2013
	IBRUTINIB CHEMBL1873475	2013
	PONATINIB CHEMBL1171837	2012
	CABOZANTINIB CHEMBL2105717	2012
	BOSUTINIB CHEMBL288441	2012
	VANDETANIB CHEMBL24828	2011
	CRIZOTINIB CHEMBL601719	2011
	PAZOPANIB CHEMBL477772	2009
	NILOTINIB CHEMBL255863	2007
	DASATINIB ANHYDROUS CHEMBL1421	2006
	SUNITINIB CHEMBL535	2006
	DASATINIB CHEMBL5416410	2006
	SORAFENIB CHEMBL1336	2005
	ERLOTINIB CHEMBL553	2004
	GEFITINIB CHEMBL939	2003
	IMATINIB CHEMBL941	2001

← Target Page

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:31:09Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 7:31 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL4223